Immune checkpoint inhibitors in renal cell carcinoma
作者： Kirsty Ross , Rob J. Jones
DOI: 10.1042/CS20160894
关键词: Biology 、 Cancer 、 Bioinformatics 、 Immunology 、 Monoclonal antibody 、 Renal cell carcinoma 、 Disease 、 Immunotherapy 、 Drug 、 Immune system 、 Nivolumab
摘要: … TCR ‘stop signal’, supporting the maintenance of the immunological synapse to allow serial interactions between TCRs … RNA from archival tumour biopsies was analysed for markers of …
portlandpress.com
clinsci.org参考文章(107)
Steven A. Rosenberg, Gwendolyn Fyfe, Gwendolyn Fyfe, Richard I. Fisher, Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. The cancer journal from Scientific American. ,vol. 6, ,(2000)
Arlene H. Sharpe, Gordon J. Freeman, The B7–CD28 superfamily Nature Reviews Immunology. ,vol. 2, pp. 116- 126 ,(2002) , 10.1038/NRI727
Julien Calderaro, Julien Moroch, Gaelle Pierron, Florence Pedeutour, Camille Grison, Pascale Maillé, Pascale Soyeux, Alexandre de la Taille, Jérome Couturier, Annick Vieillefond, Marie Christine Rousselet, Olivier Delattre, Yves Allory, SMARCB1/INI1 inactivation in renal medullary carcinoma. Histopathology. ,vol. 61, pp. 428- 435 ,(2012) , 10.1111/J.1365-2559.2012.04228.X
Hiral Parekh, Brian I Rini, Emerging therapeutic approaches in renal cell carcinoma. Expert Review of Anticancer Therapy. ,vol. 15, pp. 1305- 1314 ,(2015) , 10.1586/14737140.2015.1090315
Roy S. Herbst, Michael S. Gordon, Gregg Daniel Fine, Jeffrey Alan Sosman, Jean-Charles Soria, Omid Hamid, John D. Powderly, Howard A. Burris, Ahmad Mokatrin, Marcin Kowanetz, Maya Leabman, Maria Anderson, Daniel S. Chen, F. Stephen Hodi, A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. Journal of Clinical Oncology. ,vol. 31, pp. 3000- 3000 ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.3000
Daniel Y. C. Heng, Toni K. Choueiri, Non-clear cell renal cancer: features and medical management. Journal of The National Comprehensive Cancer Network. ,vol. 7, pp. 659- 665 ,(2009) , 10.6004/JNCCN.2009.0046
Daniel C Cho, Jeffrey Alan Sosman, Mario Sznol, Michael S Gordon, Antoine Hollebecque, Omid Hamid, David F McDermott, Jean-Pierre Delord, Ina Park Rhee, Ahmad Mokatrin, Marcin Kowanetz, Roel Peter Funke, Gregg Daniel Fine, Thomas Powles, None, Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. ,vol. 31, pp. 4505- 4505 ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.4505
J.R. Srigley, H. Gevensleben, J.-M. Lunkenheimer, G. Kristiansen, B. Delahunt, T. Thiesler, L. Egevad, C. Lüders, R. Montironi, Vancouver-Klassifikation von Nierentumoren Pathologe. ,vol. 36, pp. 310- 316 ,(2014) , 10.1007/S00292-014-2030-Z
Seppo Pyrhönen, Eeva Salminen, Mirja Ruutu, Timo Lehtonen, Martti Nurmi, Teuvo Tammela, Harri Juusela, Erkki Rintala, Päivi Hietanen, Pirko-Liisa Kellokumpu-Lehtinen, Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell Cancer Journal of Clinical Oncology. ,vol. 17, pp. 2859- 2859 ,(1999) , 10.1200/JCO.1999.17.9.2859
S. D. Fossa, Interferon in metastatic renal cell carcinoma. Seminars in Oncology. ,vol. 27, pp. 187- 193 ,(2000)